SEEL RSI Chart
Last 7 days
742.9%
Last 30 days
505.1%
Last 90 days
184.3%
Trailing 12 Months
143.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 2.0M | 0 | 0 | 0 |
2023 | 910.0K | 1.2M | 1.6M | 2.2M |
2022 | 120.0K | 0 | 127.0K | 128.0K |
2021 | 37.0K | 59.0K | 94.0K | 113.0K |
2020 | 392.0K | 409.0K | 38.0K | 45.0K |
2019 | 4.4M | 3.1M | 1.7M | 375.0K |
2016 | 5.0M | 5.0M | 8.0M | 5.8M |
2015 | 9.7M | 4.7M | 4.1M | 4.8M |
2014 | 0 | 7.0M | 7.7M | 9.6M |
2013 | 8.2M | 9.4M | 4.5M | 2.5M |
2012 | 4.7M | 5.8M | 6.9M | 7.9M |
2011 | 5.2M | 5.3M | 5.0M | 3.6M |
2010 | 0 | 3.6M | 4.3M | 5.0M |
2009 | 0 | 0 | 0 | 3.0M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 29, 2024 | golembiewski michael joseph | acquired | 457 | 1.097 | 417 | chief financial officer |
Dec 01, 2023 | mehra raj | bought | 99,999 | 1.32 | 75,757 | see remarks |
Nov 30, 2023 | golembiewski michael joseph | bought | 100,222 | 1.2075 | 83,000 | chief financial officer |
Aug 31, 2023 | golembiewski michael joseph | acquired | 7,725 | 0.618 | 12,500 | chief financial officer |
Feb 28, 2023 | golembiewski michael joseph | acquired | 8,400 | 0.672 | 12,500 | chief financial officer |
Jun 01, 2022 | o'connor daniel j. | bought | 9,788 | 0.6118 | 16,000 | - |
May 26, 2022 | dalesandro margaret | bought | 20,965 | 0.599 | 35,000 | - |
Mar 31, 2022 | mehra raj | bought | 56,840 | 0.8526 | 66,667 | see remarks |
Feb 28, 2022 | golembiewski michael joseph | acquired | 11,262 | 0.901 | 12,500 | chief financial officer |
Feb 13, 2020 | mehra raj | bought | 99,999 | 0.75 | 133,333 | see remarks |
Which funds bought or sold SEEL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 99.19 | -1,123 | 6,216 | -% |
May 15, 2024 | GENDELL JEFFREY L | added | 284 | 98,375 | 253,519 | 0.01% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -10,346 | 7,652 | -% |
May 15, 2024 | MORGAN STANLEY | added | 79.67 | -23,023 | 74,504 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -0.03 | -3,004 | 2,220 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -48.17 | -27,359 | 7,733 | -% |
May 15, 2024 | LM Advisors LLC | sold off | -100 | -115 | - | -% |
May 15, 2024 | Vermillion & White Wealth Management Group, LLC | new | - | 588 | 588 | -% |
May 15, 2024 | FIRST MANHATTAN CO. LLC. | unchanged | - | -298 | 219 | -% |
Unveiling Seelos Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Seelos Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.52 | 7.43 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.1B | 2.0B | -57.61 | 9.55 | ||||
BMRN | 14.6B | 2.5B | 71.11 | 5.91 | ||||
INCY | 12.8B | 3.8B | 17.13 | 3.39 | ||||
MID-CAP | ||||||||
BBIO | 5.8B | 107.9M | -10.63 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.22 | 9.73 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 3.1B | 240.7M | -6.6 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
NVAX | 2.0B | 996.6M | -5.07 | 2.03 | ||||
CPRX | 1.9B | 411.3M | 29.69 | 4.7 | ||||
CRBP | 489.5M | 881.7K | -14.5 | 481.06 | ||||
INO | 330.9M | 4.9M | -2.65 | 67.99 | ||||
IBIO | 15.7M | 2.1M | -0.68 | 7.61 |
Seelos Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2016Q4 |
Revenue | -11.3% | 579 | 653 | 406 | 336 | 808 | 40.00 | 36.00 | 26.00 | 26.00 | 39.00 | 29.00 | 19.00 | 7.00 | 4.00 | 7.00 | 27.00 | - | 375 | 369 | 362 | 356 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 282 |
Operating Expenses | -23.4% | 6,634 | 8,664 | 13,009 | 11,289 | 9,740 | 18,257 | 17,410 | 14,010 | 27,374 | 10,910 | 6,773 | 16,612 | 5,845 | 4,085 | 3,320 | 5,509 | 10,330 | 4,056 | 3,394 | 12,342 | - |
S&GA Expenses | -100.0% | - | 2,746 | 2,987 | 2,780 | 4,072 | 2,752 | 2,660 | 4,001 | 7,828 | 2,227 | 2,465 | 2,500 | 2,013 | 2,070 | 1,876 | 1,816 | 1,132 | 1,415 | 1,690 | 3,322 | - |
R&D Expenses | -40.4% | 3,525 | 5,918 | 10,022 | 8,509 | 5,668 | 21,783 | 14,750 | 10,009 | - | 8,683 | 4,308 | 14,112 | 3,832 | 2,015 | 1,444 | 3,693 | -4,603 | 2,641 | 100 | 100 | - |
EBITDA Margin | -10.7% | -11.16* | -10.08* | -13.97* | -18.25* | -24.46* | -173.92* | -175.25* | -180.50* | -182.99* | -218.42* | -348.23* | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 847.4% | 180 | 19.00 | 42.00 | 7.00 | 7.00 | - | 2.00 | 7.00 | 5.00 | 20.00 | 583 | 990 | 151 | 6.00 | 3.00 | 4.00 | 13.00 | 5.00 | 6.00 | 5.00 | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.00 |
EBT Margin | -11.6% | -11.31* | -10.13* | -14.04* | -18.29* | -24.52* | -174.35* | -175.72* | -185.97* | -197.49* | -237.41* | -378.24* | - | - | - | - | - | - | - | - | - | - |
Net Income | 89.5% | -2,664 | -25,450 | 10,498 | 10,498 | -13,431 | -18,657 | -19,604 | -14,001 | -27,259 | -10,815 | -8,858 | -19,116 | -6,450 | -4,090 | -3,729 | -4,832 | -10,659 | -3,221 | -1,863 | -35,512 | - |
Net Income Margin | 55.6% | -3.61* | -8.12* | -6.98* | -33.77* | -80.18* | -574.48* | -646.74* | -507.77* | -584.50* | -481.27* | -652.78* | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -142.9% | -4,642 | -1,911 | -5,749 | -5,904 | -10,348 | -13,090 | -11,074 | -17,045 | -18,339 | -10,510 | -8,894 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -33.3% | 4.00 | 5.00 | 6.00 | 12.00 | 24.00 | 23.00 | 41.00 | 53.00 | 71.00 | 84.00 | 81.00 | 90.00 | 41.00 | 17.00 | 10.00 | 8.00 | 14.00 | 11.00 | 16.00 | 10.00 | 12.00 |
Current Assets | -34.3% | 4.00 | 5.00 | 6.00 | 12.00 | 24.00 | 23.00 | 41.00 | 53.00 | 71.00 | 83.00 | 81.00 | 90.00 | 41.00 | 17.00 | 10.00 | 8.00 | 14.00 | 11.00 | 16.00 | 10.00 | 12.00 |
Cash Equivalents | -82.5% | 1.00 | 3.00 | 3.00 | 6.00 | 14.00 | 16.00 | 31.00 | 41.00 | 62.00 | 79.00 | 77.00 | 87.00 | 39.00 | 16.00 | 8.00 | 6.00 | 13.00 | 10.00 | 15.00 | 10.00 | 11.00 |
Liabilities | -5.7% | 37.00 | 39.00 | 37.00 | 59.00 | 44.00 | 33.00 | 33.00 | 26.00 | 25.00 | 26.00 | 8.00 | 8.00 | 17.00 | 15.00 | 3.00 | 4.00 | 7.00 | 11.00 | 6.00 | 5.00 | 9.00 |
Current Liabilities | -5.7% | 37.00 | 39.00 | 35.00 | 56.00 | 39.00 | 25.00 | 22.00 | 15.00 | 10.00 | 8.00 | 8.00 | 8.00 | 13.00 | 7.00 | 3.00 | 4.00 | 7.00 | 11.00 | 6.00 | - | - |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 3.00 | 7.00 | - | - | - | - | - | - | - |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 2.00 | 2.00 | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 3.00 | 7.00 | - | - | - | - | - | - | - |
Shareholder's Equity | 1.2% | -33.10 | -33.51 | - | - | -20.66 | -10.61 | 8.00 | 26.00 | 46.00 | 57.00 | 73.00 | 83.00 | 25.00 | 3.00 | 7.00 | 4.00 | 7.00 | - | 10.00 | 5.00 | 3.00 |
Retained Earnings | -1.1% | -255 | -252 | -247 | -257 | -228 | -214 | 196 | 177 | 155 | -141 | -113 | -103 | -94.28 | 75.00 | -68.71 | -64.62 | -60.89 | -56.06 | -45.40 | -42.18 | -40.32 |
Additional Paid-In Capital | 1.4% | 222 | 219 | 217 | 210 | 207 | 204 | 204 | 203 | 201 | 198 | 187 | 186 | 119 | 78.00 | 75.00 | 68.00 | 68.00 | 56.00 | 56.00 | 47.00 | 43.00 |
Shares Outstanding | 55.8% | 15.00 | 10.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 145 | - | 70.00 | - | - | - | - | - | 262 | - | - | - | 42.00 | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -142.9% | -4,642 | -1,911 | -5,749 | -5,904 | -10,348 | -13,090 | -11,074 | -20,395 | -17,045 | -18,339 | -10,510 | -8,894 | -11,252 | -3,329 | -4,180 | -6,981 | -6,423 | -5,118 | -2,910 | -3,337 | -7,940 |
Share Based Compensation | -0.9% | 955 | 964 | 974 | 988 | 1,062 | 907 | 973 | 961 | 2,232 | 4,900 | 857 | 1,037 | 705 | 697 | 695 | 341 | 311 | 4,585 | 133 | 144 | 38.00 |
Cashflow From Financing | -6.6% | 2,170 | 2,323 | 2,490 | -2,312 | 8,874 | -1,888 | 334 | -126 | 83.00 | 20,240 | 143 | 57,407 | 34,277 | 10,937 | 6,380 | 147 | 8,850 | 64.00 | 8,497 | 1,773 | 19,190 |
Buy Backs | - | - | - | - | - | 1,195 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue | ||
Total revenue | $ 579 | $ 808 |
Revenue, Product and Service [Extensible Enumeration] | us-gaap:GrantMember | us-gaap:GrantMember |
Operating expense | ||
Research and development | $ 3,525 | $ 5,668 |
General and administrative | 3,109 | 4,072 |
Total operating expense | 6,634 | 9,740 |
Loss from operations | (6,055) | (8,932) |
Other income (expense) | ||
Interest income | 10 | 67 |
Interest expense | (23) | (7) |
Change in fair value of convertible notes | (203) | 66 |
Loss on extinguishment of debt | (1,493) | (13) |
Loss on issuance of common stock and warrants | (4,301) | |
Change in fair value of warrant liabilities | 5,100 | (311) |
Total other income (expense) | 3,391 | (4,499) |
Net loss and comprehensive loss | $ (2,664) | $ (13,431) |
Total loss per share basic (note 1) | $ (0.20) | $ (3.58) |
Total loss per share-diluted (note 1) | $ (0.20) | $ (3.58) |
Weighted-average common shares outstanding used for basic (note 1) | 13,007,556 | 3,751,468 |
Weighted-average common shares outstanding used for diluted (note 1) | 13,007,556 | 3,751,468 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash | $ 524 | $ 2,996 |
Grant receivable | 968 | 763 |
Prepaid expenses and other current assets | 2,058 | 1,644 |
Total current assets | 3,550 | 5,403 |
Operating lease right-of-use asset | 62 | 15 |
Total assets | 3,612 | 5,418 |
Current liabilities | ||
Accounts payable | 15,268 | 16,403 |
Accrued expenses | 4,524 | 2,516 |
Short-term portion of convertible notes payable, at fair value | 13,075 | 14,213 |
Warrant liabilities, at fair value | 3,787 | 5,781 |
Operating lease liability | 62 | 15 |
Total current liabilities | 36,716 | 38,928 |
Total liabilities | 36,716 | 38,928 |
Commitments and contingencies (note 12) | ||
Stockholders' equity (deficit) | ||
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of March 31, 2024 and December 31, 2023 | ||
Common stock, $0.001 par value, 400,000,000 and 16,000,000 shares authorized, 15,256,268 and 9,794,594 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (note 1) | 15 | 10 |
Additional paid-in-capital | 222,171 | 219,106 |
Accumulated deficit | (255,290) | (252,626) |
Total stockholders' equity (deficit) | (33,104) | (33,510) |
Total liabilities and stockholders' equity (deficit) | $ 3,612 | $ 5,418 |